

# Jürgen Jahnsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595317/publications.pdf>

Version: 2024-02-01

129  
papers

8,815  
citations

57758

44  
h-index

43889

91  
g-index

134  
all docs

134  
docs citations

134  
times ranked

8166  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment and outcome of gastrointestinal bleeding due to peptic ulcers and erosions " (BLUE study). Scandinavian Journal of Gastroenterology, 2022, 57, 8-15.	1.5	8
2	The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients. Scandinavian Journal of Gastroenterology, 2022, , 1-7.	1.5	2
3	P696 Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases " secondary analyses from a randomised clinical trial. Journal of Crohn's and Colitis, 2022, 16, i594-i595.	1.3	1
4	OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study. Journal of Crohn's and Colitis, 2022, 16, i010-i010.	1.3	2
5	P636 Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSen study. Journal of Crohn's and Colitis, 2022, 16, i555-i555.	1.3	0
6	Photodynamic Effects with 5-Aminolevulinic Acid on Cytokines and Exosomes in Human Peripheral Blood Mononuclear Cells. Biomedicines, 2022, 10, 232.	3.2	4
7	P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study. Journal of Crohn's and Colitis, 2022, 16, i537-i538.	1.3	1
8	DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i116-i117.	1.3	0
9	P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice. Journal of Crohn's and Colitis, 2022, 16, i441-i441.	1.3	0
10	Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. Clinical and Experimental Gastroenterology, 2022, Volume 15, 5-25.	2.3	5
11	Phenotype-Based Isolation of Antigen-Specific CD4 <sup>+</sup> T Cells in Autoimmunity: A Study of Celiac Disease. Advanced Science, 2022, 9, e2104766.	11.2	7
12	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatology, The, 2022, 4, e177-e187.	3.9	122
13	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. Cancer Research, 2022, 82, OT2-19-01-OT2-19-01.	0.9	0
14	Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2. Journal of Crohn's and Colitis, 2022, 16, 1255-1268.	1.3	17
15	Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. Journal of Internal Medicine, 2022, 292, 477-491.	6.0	12
16	Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases"Reply. JAMA - Journal of the American Medical Association, 2022, 327, 1506.	7.4	1
17	Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis and Rheumatology, 2022, 74, 1321-1332.	5.6	31
18	Discontinuation of Infliximab Therapy in Patients with Crohn's Disease. , 2022, 1, .		17

#	ARTICLE	IF	CITATIONS
19	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterology, 2022, 22, .	2.0	15
20	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, 106-122.	1.9	14
21	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. Journal of Crohn's and Colitis, 2021, 15, 699-708.	1.3	36
22	Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World Journal of Gastroenterology, 2021, 27, 2039-2053.	3.3	2
23	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases. JAMA - Journal of the American Medical Association, 2021, 325, 1744.	7.4	83
24	OPO301...RISK FACTORS FOR ANTI-INFLIXIMAB ANTIBODY FORMATION: RESULTS FROM THE RANDOMISED CONTROLLED NOR-DRUM A TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 185.2-185.	0.9	0
25	Systemic Inflammation in Preclinical Ulcerative Colitis. Gastroenterology, 2021, 161, 1526-1539.e9.	1.3	58
26	A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 2021, 385, 35-45.	27.0	98
27	A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. Science Immunology, 2021, 6, .	11.9	15
28	Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for Tâ€œCellâ€œDirected Therapies. Advanced Science, 2021, 8, e2102778.	11.2	10
29	Longevity, clonal relationship, and transcriptional program of celiac diseaseâ€œspecific plasma cells. Journal of Experimental Medicine, 2021, 218, .	8.5	25
30	Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. Journal of Crohn's and Colitis, 2021, 15, 969-979.	1.3	29
31	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases. JAMA - Journal of the American Medical Association, 2021, 326, 2375.	7.4	78
32	The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study). Inflammatory Bowel Diseases, 2020, 26, 114-124.	1.9	12
33	On the immune response to barley in celiac disease: Biased and public Tâ€œcell receptor usage to a barley unique and immunodominant gluten epitope. European Journal of Immunology, 2020, 50, 256-269.	2.9	13
34	Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM) Tj ETQq0 0 0 rgBT6/Overlook 10 Tf 50		
35	Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients, 2020, 12, 26.	4.1	8
36	Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scandinavian Journal of Gastroenterology, 2020, 55, 1146-1156.	1.5	20

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. <i>BioDrugs</i> , 2020, 34, 681-694.	4.6	10
38	Gastrointestinal bleeding due to peptic ulcers and erosions – a prospective observational study (BLUE). <i>Tj ETQq0 0,0 rgBT /Qverlock 10</i>	1.5	9
39	Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. <i>Paediatric Drugs</i> , 2020, 22, 409-416.	3.1	41
40	Self-esteem in patients with inflammatory bowel disease. <i>Quality of Life Research</i> , 2020, 29, 1839-1846.	3.1	14
41	Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 400-400.	3.7	1
42	Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1724-1733.	1.3	16
43	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	10.9	58
44	Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study. <i>Obesity Surgery</i> , 2020, 30, 3426-3434.	2.1	9
45	OP0017 – THERAPEUTIC DRUG MONITORING COMPARED TO STANDARD TREATMENT OF PATIENTS STARTING INFLIXIMAB THERAPY: RESULTS FROM A MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 12-12.	0.9	7
46	Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 610-611.	3.7	1
47	Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 397-406.	3.7	46
48	P250 Use of complementary and alternative medicine is associated with chronic fatigue and lower health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: results from the IBSEN study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S221-S222.	1.3	0
49	Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 571-576.	1.5	11
50	Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease. <i>Gastroenterology</i> , 2019, 156, 1428-1439.e10.	1.3	61
51	P723 Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S482-S483.	1.3	0
52	&lt;p&gt;Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 37-49.	2.3	58
53	Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. <i>Journal of Internal Medicine</i> , 2019, 285, 653-669.	6.0	87
54	Assessment of Bowel Inflammation and Strictures by Magnetic Resonance Enterography in Long-term Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 607-614.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery. <i>Clinical Endocrinology</i> , 2018, 88, 372-379.	2.4	20
56	Bowel Damage in Patients With Long-term Crohn's Disease, Assessed by Magnetic Resonance Enterography and the Lönnemann Index. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 75-82.e5.	4.4	13
57	Determinants of optimal bowel function in ileal pouch-anal anastomosis – physiological differences contributing to pouch function. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 8-14.	1.5	13
58	The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients. <i>Scientific Reports</i> , 2018, 8, 17278.	3.3	17
59	Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey*. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1437-1442.	1.5	19
60	P208 Chronic fatigue in patients with inflammatory bowel disease is associated with lower health-related quality of life, low self-esteem, increased anxiety and depression. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S204-S205.	1.3	2
61	AB0442...Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a norwegian randomised trial. , 2018, , .		8
62	Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 3293-3301.	3.3	27
63	FR10140...Individualised infliximab treatment: a treatment strategy based on therapeutic drug monitoring. , 2018, , .		2
64	Experience with Biosimilar Infliximab (Remsima®) in Norway. <i>Digestive Diseases</i> , 2017, 35, 83-90.	1.9	28
65	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017, 31, 223-237.	4.6	30
66	Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. <i>Lancet</i> , The, 2017, 389, 2304-2316.	13.7	666
67	Similar Responses of Intestinal T Cells From Untreated Children and Adults With Celiac Disease to Deamidated Gluten Epitopes. <i>Gastroenterology</i> , 2017, 153, 787-798.e4.	1.3	24
68	THU0354...Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the randomized nor-switch-study: explorative analysis in SPA patients. , 2017, , .		1
69	Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue. <i>United European Gastroenterology Journal</i> , 2017, 5, 687-693.	3.8	13
70	Efficacy of infliximab biosimilars in patients with Crohn's disease – Authors' reply. <i>Lancet</i> , The, 2017, 390, 2436.	13.7	1
71	Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 351-358.	1.5	52
72	Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 100-106.	1.5	79

#	ARTICLE	IF	CITATIONS
73	FRI0182â€¦Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the nor-switch study: explorative analysis of RA patients. , 2017, , .		1
74	THU0700â€¦Immunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study. , 2017, , .		0
75	OPO22 Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study. Journal of Crohn's and Colitis, 2017, 11, S13-S13.	1.3	6
76	P061 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease â€œ IBD Character. Journal of Crohn's and Colitis, 2017, 11, S108-S108.	1.3	0
77	P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease. Journal of Crohn's and Colitis, 2017, 11, S483-S484.	1.3	0
78	Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-10.	1.9	26
79	Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis. Inflammatory Bowel Diseases, 2016, 22, 1679-1687.	1.9	35
80	Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy. BMC Research Notes, 2016, 9, 328.	1.4	22
81	Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology, 2016, 9, 322-329.	3.2	27
82	Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 660-669.e4.	1.3	162
83	Mortality and Causes of Death in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 141-145.	1.9	14
84	A role for CCL28â€œCCR3 in T-cell homing to the human upper airway mucosa. Mucosal Immunology, 2015, 8, 107-114.	6.0	34
85	Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Review of Gastroenterology and Hepatology, 2015, 9, 45-52.	3.0	100
86	Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells. Nature Communications, 2014, 5, 4041.	12.8	46
87	Tetramerâ€œvisualized glutenâ€œspecific CD4+ T cells in blood as a potential diagnostic marker for coeliac disease without oral gluten challenge. United European Gastroenterology Journal, 2014, 2, 268-278.	3.8	79
88	Mortality and causes of death in Crohn's disease: results from 20â€œ...years of follow-up in the IBSEN study. Gut, 2014, 63, 771-775.	12.1	39
89	Plasmacytoid dendritic cells are scarcely represented in the human gut mucosa and are not recruited to the celiac lesion. Mucosal Immunology, 2013, 6, 985-992.	6.0	17
90	Direct cloning and tetramer staining to measure the frequency of intestinal glutenâ€œreactive T cells in celiac disease. European Journal of Immunology, 2013, 43, 2605-2612.	2.9	45

#	ARTICLE	IF	CITATIONS
91	Secondary Hyperparathyroidism, Vitamin D Sufficiency, and Serum Calcium 5 Years After Gastric Bypass and Duodenal Switch. <i>Obesity Surgery</i> , 2013, 23, 384-390.	2.1	62
92	Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2111-2117.	1.9	178
93	Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: Ten-year results from the IBSEN study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 441-453.	1.3	55
94	Density of CD163 <sup>+</sup> CD11c <sup>+</sup> Dendritic Cells Increases and CD103 <sup>+</sup> Dendritic Cells Decreases in the Coeliac Lesion. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 186-194.	2.7	44
95	Relationships between inflammatory bowel disease and perinatal factors: Both maternal and paternal disease are related to preterm birth of offspring. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 847-855.	1.9	56
96	Fecal calprotectin variability in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1091-1092.	1.9	65
97	Predictive Value of Serologic Markers in a Population-based Norwegian Cohort with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 406-414.	1.9	48
98	Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1867-1874.	1.9	28
99	Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 92-99.	1.3	31
100	Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 431-440.	1.5	628
101	Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 984-991.	1.9	24
102	The INSPIRE study: Do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn's disease?. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1505-1513.	1.5	33
103	C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. <i>Gut</i> , 2008, 57, 1518-1523.	12.1	331
104	The Association Between Water Supply and Inflammatory Bowel Disease Based on a 1990-1993 Cohort Study in Southeastern Norway. <i>American Journal of Epidemiology</i> , 2008, 168, 1065-1072.	3.4	53
105	Clinical Course in Crohn's Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1430-1438.	4.4	617
106	Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN) <small>Tj ETQq0 0 0 rBT /Overlock 10 Tf 15 199</small>		
107	Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1584-1586.	1.9	25
108	Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1037-1043.	1.5	111

#	ARTICLE	IF	CITATIONS
109	Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 402-412.	1.9	168
110	Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN) Tj ETQq0 0 0 rgt /Overlock 10 Tf	1.9	228
111	Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1037-1045.	1.6	87
112	Health-related Quality of Life in Patients with Inflammatory Bowel Disease Measured with the Short Form-36: Psychometric Assessments and a Comparison with General Population Norms. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 909-918.	1.9	190
113	Pediatric Inflammatory Bowel Disease in Southeastern Norway: A Five-Year Follow-Up Study. <i>Digestion</i> , 2004, 70, 226-230.	2.3	48
114	Bone mineral density in patients with inflammatory bowel disease: A population-based prospective two-year follow-up study. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 145-153.	1.5	78
115	Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 365-373.	1.5	126
116	Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 858-863.	1.5	89
117	Body Composition in Patients With Inflammatory Bowel Disease: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 1556-1562.	0.4	128
118	Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression. <i>Gut</i> , 2002, 51, 372-378.	12.1	60
119	Vitamin D Status, Parathyroid Hormone and Bone Mineral Density in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 192-199.	1.5	169
120	Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. <i>Lancet</i> , The, 2002, 359, 1661-1665.	13.7	397
121	Interferon- $\gamma$ -Secreting T Cells Localize to the Epithelium in Coeliac Disease. <i>Scandinavian Journal of Immunology</i> , 2002, 56, 652-664.	2.7	57
122	Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. <i>Journal of Rheumatology</i> , 2001, 28, 590-4.	2.0	31
123	Duodenal ulcer healing rates in a one-year follow-up study with ranitidine bismuth citrate and antibiotics. <i>Hepato-Gastroenterology</i> , 2001, 48, 1641-7.	0.5	0
124	Ultrasound Measurements of Calcaneus for Estimation of Skeletal Status in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 790-797.	1.5	20
125	Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. <i>Gastroenterology</i> , 1998, 115, 551-563.	1.3	430
126	Incidence and Prevalence of Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis in a Norwegian Population. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 99-103.	1.5	457



#	ARTICLE	IF	CITATIONS
127	Ranitidine Bismuth Citrate With Clarithromycin Given Twice Daily Effectively Eradicates Helicobacter pylori and Heals Duodenal Ulcers. American Journal of Gastroenterology, 1998, 93, 380-385.	0.4	16
128	Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. Digestion, 1997, 58, 176-180.	2.3	333
129	Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.. Gut, 1997, 40, 313-319.	12.1	237